Mast cells and inflammatory heart disease: Potential drug targets

DeLisa Fairweather, Sylvia Frisancho-Kiss

Research output: Contribution to journalReview article

27 Citations (Scopus)

Abstract

Inflammation underlies the pathogenesis of many common cardiovascular diseases (CVD) such as myocardial infarction, atherosclerosis, myocarditis and dilated cardiomyopathy. Allergic disorders like allergic rhinitis and asthma, both chronic inflammatory conditions, have recently been linked to increased CVD and death. Studies have found that increased IgE levels, eosinophilia, positive skin-prick tests, self-reported asthma and enzymes that regulate leukotriene synthesis (5-lipoxygenase) predict a high risk for atherosclerosis, stroke and myocardial infarction. Mast cells (MCs), cells involved in the pathogenesis of allergy and asthma, are emerging as key players in the regulation of inflammation and fibrosis in the heart and vasculature. Our laboratory has found that MC numbers are increased in mice susceptible to developing chronic dilated cardiomyopathy. The fibrosis associated with chronic heart disease is increased by MC degranulation. MCs can also act as antigen-presenting cells increasing inflammation in the heart through Toll-like receptor-4 signaling and increased proinflammatory cytokine production. Similar inflammatory mechanisms are observed for myocarditis and atherosclerosis. Many of the drugs currently used to reduce heart disease act on mediators/pathways downstream of MC degranulation. An improved understanding of the role of MCs in regulating inflammation and fibrosis will enable researchers and clinicians to better treat heart disease.

Original languageEnglish (US)
Pages (from-to)80-90
Number of pages11
JournalCardiovascular and Hematological Disorders - Drug Targets
Volume8
Issue number1
DOIs
StatePublished - Mar 2008
Externally publishedYes

Fingerprint

Mast Cells
Heart Diseases
Pharmaceutical Preparations
Inflammation
Cell Degranulation
Atherosclerosis
Fibrosis
Asthma
Myocarditis
Dilated Cardiomyopathy
Cardiovascular Diseases
Myocardial Infarction
Arachidonate 5-Lipoxygenase
Toll-Like Receptor 4
Leukotrienes
Eosinophilia
Antigen-Presenting Cells
Skin Tests
Immunoglobulin E
Hypersensitivity

Keywords

  • Atherosclerosis
  • Fibrosis
  • Inflammation
  • Mast cells
  • Myocarditis

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Hematology
  • Pharmacology

Cite this

Mast cells and inflammatory heart disease : Potential drug targets. / Fairweather, DeLisa; Frisancho-Kiss, Sylvia.

In: Cardiovascular and Hematological Disorders - Drug Targets, Vol. 8, No. 1, 03.2008, p. 80-90.

Research output: Contribution to journalReview article

@article{d18be21dddd64b0c861a280bba24f640,
title = "Mast cells and inflammatory heart disease: Potential drug targets",
abstract = "Inflammation underlies the pathogenesis of many common cardiovascular diseases (CVD) such as myocardial infarction, atherosclerosis, myocarditis and dilated cardiomyopathy. Allergic disorders like allergic rhinitis and asthma, both chronic inflammatory conditions, have recently been linked to increased CVD and death. Studies have found that increased IgE levels, eosinophilia, positive skin-prick tests, self-reported asthma and enzymes that regulate leukotriene synthesis (5-lipoxygenase) predict a high risk for atherosclerosis, stroke and myocardial infarction. Mast cells (MCs), cells involved in the pathogenesis of allergy and asthma, are emerging as key players in the regulation of inflammation and fibrosis in the heart and vasculature. Our laboratory has found that MC numbers are increased in mice susceptible to developing chronic dilated cardiomyopathy. The fibrosis associated with chronic heart disease is increased by MC degranulation. MCs can also act as antigen-presenting cells increasing inflammation in the heart through Toll-like receptor-4 signaling and increased proinflammatory cytokine production. Similar inflammatory mechanisms are observed for myocarditis and atherosclerosis. Many of the drugs currently used to reduce heart disease act on mediators/pathways downstream of MC degranulation. An improved understanding of the role of MCs in regulating inflammation and fibrosis will enable researchers and clinicians to better treat heart disease.",
keywords = "Atherosclerosis, Fibrosis, Inflammation, Mast cells, Myocarditis",
author = "DeLisa Fairweather and Sylvia Frisancho-Kiss",
year = "2008",
month = "3",
doi = "10.2174/187152908783884957",
language = "English (US)",
volume = "8",
pages = "80--90",
journal = "Cardiovascular and Hematological Disorders - Drug Targets",
issn = "1871-529X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Mast cells and inflammatory heart disease

T2 - Potential drug targets

AU - Fairweather, DeLisa

AU - Frisancho-Kiss, Sylvia

PY - 2008/3

Y1 - 2008/3

N2 - Inflammation underlies the pathogenesis of many common cardiovascular diseases (CVD) such as myocardial infarction, atherosclerosis, myocarditis and dilated cardiomyopathy. Allergic disorders like allergic rhinitis and asthma, both chronic inflammatory conditions, have recently been linked to increased CVD and death. Studies have found that increased IgE levels, eosinophilia, positive skin-prick tests, self-reported asthma and enzymes that regulate leukotriene synthesis (5-lipoxygenase) predict a high risk for atherosclerosis, stroke and myocardial infarction. Mast cells (MCs), cells involved in the pathogenesis of allergy and asthma, are emerging as key players in the regulation of inflammation and fibrosis in the heart and vasculature. Our laboratory has found that MC numbers are increased in mice susceptible to developing chronic dilated cardiomyopathy. The fibrosis associated with chronic heart disease is increased by MC degranulation. MCs can also act as antigen-presenting cells increasing inflammation in the heart through Toll-like receptor-4 signaling and increased proinflammatory cytokine production. Similar inflammatory mechanisms are observed for myocarditis and atherosclerosis. Many of the drugs currently used to reduce heart disease act on mediators/pathways downstream of MC degranulation. An improved understanding of the role of MCs in regulating inflammation and fibrosis will enable researchers and clinicians to better treat heart disease.

AB - Inflammation underlies the pathogenesis of many common cardiovascular diseases (CVD) such as myocardial infarction, atherosclerosis, myocarditis and dilated cardiomyopathy. Allergic disorders like allergic rhinitis and asthma, both chronic inflammatory conditions, have recently been linked to increased CVD and death. Studies have found that increased IgE levels, eosinophilia, positive skin-prick tests, self-reported asthma and enzymes that regulate leukotriene synthesis (5-lipoxygenase) predict a high risk for atherosclerosis, stroke and myocardial infarction. Mast cells (MCs), cells involved in the pathogenesis of allergy and asthma, are emerging as key players in the regulation of inflammation and fibrosis in the heart and vasculature. Our laboratory has found that MC numbers are increased in mice susceptible to developing chronic dilated cardiomyopathy. The fibrosis associated with chronic heart disease is increased by MC degranulation. MCs can also act as antigen-presenting cells increasing inflammation in the heart through Toll-like receptor-4 signaling and increased proinflammatory cytokine production. Similar inflammatory mechanisms are observed for myocarditis and atherosclerosis. Many of the drugs currently used to reduce heart disease act on mediators/pathways downstream of MC degranulation. An improved understanding of the role of MCs in regulating inflammation and fibrosis will enable researchers and clinicians to better treat heart disease.

KW - Atherosclerosis

KW - Fibrosis

KW - Inflammation

KW - Mast cells

KW - Myocarditis

UR - http://www.scopus.com/inward/record.url?scp=43649088631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43649088631&partnerID=8YFLogxK

U2 - 10.2174/187152908783884957

DO - 10.2174/187152908783884957

M3 - Review article

C2 - 18336255

AN - SCOPUS:43649088631

VL - 8

SP - 80

EP - 90

JO - Cardiovascular and Hematological Disorders - Drug Targets

JF - Cardiovascular and Hematological Disorders - Drug Targets

SN - 1871-529X

IS - 1

ER -